LGND
Ligand Pharmaceuticals Incorporated
Stock
$302.96+0.22 (+0.07%)Close Oct 2, 2026
Income statement
| Line | Last 12 months | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $291M | $268M | $167M | $131M | $196M | $242M | $164M | $120M | $251M | $141M | $109M | $72M | $65M | $49M | $31M | $30M | $24M | $39M |
| Cost of revenue | — | — | — | — | — | — | — | — | $6.3M | $5.4M | $5.6M | $5.8M | $9.1M | $5.7M | $3.6M | $4.9M | — | — |
| Gross profit | — | — | — | — | — | — | — | — | $245M | $136M | $103M | $66M | $55M | $43M | $28M | $25M | — | — |
| R&D | $41M | $81M | $21M | $25M | $36M | $32M | $41M | $56M | $28M | $27M | $21M | $11M | $9.7M | $9.3M | $11M | $10M | $22M | $40M |
| Other operating expenses | — | — | — | — | — | — | — | — | $54M | $41M | $38M | $28M | $26M | $19M | $17M | $16M | — | — |
| Operating income | $95M | $41M | −$23M | $12M | $3.0M | $104M | $38M | $807M | $164M | $68M | $44M | $27M | $20M | $15M | $193K | −$878K | −$29M | −$10.0M |
| Non-operating income | $143M | $118M | $25M | $52M | $33M | −$32M | −$36M | −$10M | $9.6M | −$11M | −$36M | $8.0M | −$8.3M | −$5.7M | −$4.1M | −$2.7M | $14M | $95K |
| Pretax income | $238M | $159M | $2.5M | $64M | $36M | $72M | $1.3M | $797M | $173M | $57M | $8.0M | $35M | $11M | $9.2M | −$3.9M | −$3.6M | −$15M | −$9.9M |
| Taxes | $41M | $35M | $6.6M | $12M | $69M | $15M | $4.3M | $167M | $30M | $45M | $9.6M | −$194M | −$722K | −$2.2M | −$3.3M | −$13M | −$5.0M | −$7.9M |
| Net income | $197M | $124M | −$4.0M | $52M | −$33M | $57M | −$3.0M | $629M | $143M | $13M | −$1.6M | $230M | $12M | $11M | −$527K | $9.7M | −$10M | −$1.9M |
| Diluted EPS | $9.32 | $6.13 | −$0.22 | $2.94 | −$1.98 | $3.31 | −$0.18 | $31.85 | $5.96 | $0.53 | −$0.08 | $10.83 | $0.56 | $0.55 | −$0.03 | $0.49 | −$0.53 | −$0.10 |
| Diluted shares | — | 20.3M | 18.3M | 17.8M | 16.9M | 17.2M | 16.8M | 19.8M | 24.1M | 23.5M | 20.8M | 21.2M | 21.4M | 20.7M | 19.9M | 19.7M | 19.6M | 18.9M |
| Revenue growth | — | +60.4% | +27.3% | −33.1% | −18.8% | +47.7% | +36.0% | −52.2% | +78.2% | +29.5% | +51.5% | +11.4% | +31.8% | +56.0% | +4.5% | +27.6% | −39.6% | — |
| Gross margin | — | — | — | — | — | — | — | — | 97.5% | 96.2% | 94.9% | 91.9% | 85.8% | 88.3% | 88.5% | 83.7% | — | — |
| Operating margin | 32.6% | 15.3% | −13.5% | 9.1% | 1.5% | 43.0% | 22.9% | 671.0% | 65.1% | 48.2% | 40.3% | 38.0% | 30.4% | 30.5% | 0.6% | −2.9% | −124.5% | −25.6% |
| Net margin | 67.9% | 46.4% | −2.4% | 39.7% | −17.0% | 23.7% | −1.8% | 523.2% | 57.0% | 8.9% | −1.5% | 319.6% | 18.6% | 23.3% | −1.7% | 32.3% | −44.1% | −5.0% |